Bill > HR174

This resolution urges and requests the state surgeon general and the Louisiana Department of Health to assess the feasibility of using fenbendazole, a drug currently approved for veterinary use, as a potential human cancer treatment, acknowledging public interest driven by anecdotal reports and preclinical studies suggesting anti-tumor properties. The resolution emphasizes that fenbendazole is not yet approved by the United States Food and Drug Administration (FDA) for human use, and clinical evidence is limited, with organizations like the American Cancer Society cautioning against off-label use due to potential risks. Therefore, the state surgeon general is asked to provide a professional assessment, evaluate state-level options to support further scientific review, and develop a plan for engaging federal authorities like the FDA to expedite evaluation through mechanisms such as compassionate use protocols, expanded access programs, or prioritized clinical trials, all while maintaining rigorous patient safety and evidence-based standards. The findings and recommendations are to be reported to the House Committee on Health and Welfare by February 1, 2027.